A Multicenter prospective observational long-term follow up study of endocardial cardiac resynchronization therapy using the Jurdham procedure.
Citation: Heart Rhythm. 16(10):1453-1461, 2019 10.PMID: 31323347Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Cardiac Resynchronization Therapy/mt [Methods] | *Heart Failure/mo [Mortality] | *Heart Failure/th [Therapy] | *Stroke Volume/ph [Physiology] | *Ventricular Remodeling/ph [Physiology] | Aged | Cardiac Resynchronization Therapy Devices | Cardiac Resynchronization Therapy/mo [Mortality] | Cause of Death | Cohort Studies | Female | Heart Failure/dg [Diagnostic Imaging] | Heart Function Tests | Humans | Male | Middle Aged | Patient Safety/sn [Statistics & Numerical Data] | Patient Selection | Prognosis | Retrospective Studies | Risk Assessment | Severity of Illness Index | Survival Rate | Treatment OutcomeYear: 2019Local holdings: Available online through MWHC library: 2004 - presentISSN:- 1547-5271
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 31323347 | Available | 31323347 |
Available online through MWHC library: 2004 - present
BACKGROUND: Endocardial cardiac resynchronization therapy (eCRT) avoids the limitations and failures of coronary sinus (CS) resynchronization. However, data regarding long-term outcomes are lacking.
CONCLUSION: eCRT using the Jurdham Procedure is an effective and safe technique in anticoagulated patients. This approach may be an attractive option for patients with failed CS implants or non-responders to CS CRT. Additionally, it might be a reasonable approach as a first option for patients requiring life-long OAC.
Copyright (c) 2019. Published by Elsevier Inc.
OBJECTIVE: To report the long-term outcome of eCRT performed using the Jurdham procedure in a "real world" setting. METHODS eCRT was performed in patients who failed a CS implant, failed to respond to cardiac resynchronization therapy (CRT), or in selected patients requiring life-long oral anticoagulation. Left Ventricular Ejection Fraction (LVEF), New York Heart Association Functional Class (NYHA FC), and left ventricle (LV) stimulation parameters were assessed during long-term follow up.
RESULTS: From August 2009 to March 2018, the Jurdham Procedure was performed in 88 patients at 15 centers in 8 countries with a follow up (FU) of 32.88 +/- 61.52 months (range 0 - 88 months, 196 patient-years). NYHA FC improved from 2.9 pre-implant to 1.3 during FU. LVEF increased <10 percentage points from baseline in 7% of patients, between 10 and 20 percentage points in 11% and >20% in 82% of patients. All-cause mortality at 60 months was 30.5%. There were 3 transient ischemic attacks (TIA) (1.53 per 100 patient-year) and 6 strokes (3.06 per 100 patient-year) of which 4 (66%) had an almost complete recovery.
English